← Browse by Condition
Medical Condition

scleroderma systemic

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for scleroderma systemic sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — scleroderma systemic Clinical Trials

How many clinical trials are currently recruiting for scleroderma systemic?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for scleroderma systemic, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for scleroderma systemic?
scleroderma systemic research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a scleroderma systemic clinical trial?
Eligibility criteria for scleroderma systemic trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Hacettepe University 1 trial
University Hospital, Strasbourg, France 1 trial
GlaxoSmithKline 1 trial
University Hospital, Lille 1 trial

Recruiting Clinical Trials

NCT07292961
Recruiting
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Enrollment
48 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University
View Trial →
NCT06182293
Recruiting
Periodontal Microbiota in Systemic Sclerosis
Enrollment
30 pts
Location
France
Sponsor
University Hospital, Strasbour...
View Trial →
NCT05878717 Phase 2, Phase 3
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Enrollment
300 pts
Location
United States, Argen...
Sponsor
GlaxoSmithKline
View Trial →
NCT04804930
Recruiting
Trichoscopy and Systemic Scleroderma
Enrollment
200 pts
Location
France
Sponsor
University Hospital, Lille
View Trial →

Related Conditions

scleroderma (1) scleroderma localized (1) scleroderma limited and diffuse (1) systemic sclerosis ssc (1) systemic sclerosis 2013 acr eular classification criteria (1) juvenile systemic sclerosis (1) systemic sclerosis associated interstitial lung disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology